Investment Thesis
Zomedica demonstrates strong unit economics (67.7% gross margin) and revenue growth, but faces an acute cash crisis with only $9M in liquidity against $17.6M annual operating burn, providing less than 6 months of runway. The company's path to profitability is opaque; operating losses of -$84.4M on $32M revenue suggest commercialization-phase R&D and sales expenses are unsustainable at the current burn rate without significant capital injection or dramatic operational restructuring.
Strengths
- High gross margin of 67.7% indicates strong product economics and pricing power
- Revenue growth of 17.4% YoY demonstrates market traction and customer demand
- Pristine balance sheet with zero long-term debt and no financial obligations limiting flexibility
Risks
- Critical liquidity crisis: $9M cash position vs. $17.6M annual operating burn rate implies less than 6 months until insolvency without funding
- Operating expenses are 263% of revenue; path to profitability is not evident and may require years of execution
- Negative free cash flow of -$18.2M annually; dilution risk is high if company pursues equity financing to survive
Key Metrics to Watch
- Cash burn rate and remaining cash runway—sustainability depends entirely on achieving positive cash flow or securing funding
- Operating expense trends relative to revenue growth—margin expansion is essential for viability
- Gross margin trajectory—any erosion would signal product pricing pressure or rising COGS, compounding distress
Financial Metrics
Revenue
32.0M
Net Income
-81.9M
EPS (Diluted)
$-0.08
Free Cash Flow
-18.2M
Total Assets
127.0M
Cash
9.0M
Profitability Ratios
Gross Margin
67.7%
Operating Margin
-263.4%
Net Margin
-255.6%
ROE
-70.9%
ROA
-64.4%
FCF Margin
-56.9%
Balance Sheet & Liquidity
Current Ratio
6.78x
Quick Ratio
6.19x
Debt/Equity
0.00x
Debt/Assets
9.2%
Interest Coverage
-482.02x
Long-term Debt
527.4K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-19T23:33:23.333106 |
Data as of: 2025-12-31 |
Powered by Claude AI